Please login to the form below
emerging markets
This page shows the latest emerging markets news and features for those working in and with pharma, biotech and healthcare.
AZ revenues rise, but it says coronavirus could hit 2020
Product sales were up 12% to $23.57bn for the full-year, driven by cancer products and turnover in emerging markets, although there was a bit of a slowdown to 8% ... Emerging market sales rose 18% to $2.09bn in the fourth quarter, accounting for a
Latest news
-
Merck spins off low-growth drugs in a ‘purposeful shift’ of focus
His experience includes serving as president of MSD international and the company’s emerging markets unit, and he will be joined by Carrie Cox, ex-CEO of Humacyte, who will chair
-
Lynparza cleared for first-line ovarian cancer use in China
This approval in China, which is emerging as one of the fastest growing pharmaceutical markets in the world, consolidates Lynparza’s position as the runaway leader among PARP inhibitor treatments. ... increase in the US and a 227% increase in emerging
-
AstraZeneca divests Seroquel rights to focus on key therapy areas
In 2018, Seroquel reported sales of $36m in the markets included in this agreement, while Seroquel XR generated $79m. ... Farxiga. The pharma company has also reported strong growth in emerging markets, especially China, where it saw a sales growth of 40%
-
Takeda divests over-the-counter and prescription drugs to Stada for $660m
In October, Takeda announced that it had agreed to divest a number of OTC and prescription medicines in emerging markets to Acino for $200m. ... Takeda remains committed to the emerging markets, Russia and the countries included in this agreement.
-
AZ reports growth again in Q3, driven by oncology and China sales
and also a growth of these medicines in emerging markets. ... The London-listed drugmaker also reported strong growth in emerging markets, especially China, where it saw a sales growth of 40% to $1.2bn.
More from news
Approximately 13 fully matching, plus 350 partially matching documents found.
Latest Intelligence
-
The mission matters
Developed and emerging markets differ greatly but there are also great differences between developed markets, such as Europe and the US. ... And within markets, therapy areas differ hugely, ranging from rare diseases and oncology to primary care and
-
Leading AstraZeneca’s return to growth in Europe
Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase. ... So does AstraZeneca believe there
-
It’s not the end of the world, is it?
the US market when they would, de facto, be barred from other developed and price-controlled markets. ... As emerging markets become richer, access to at least basic healthcare is one of the first developed market characteristics that their citizens seek
-
Escaping the spin cycle of sub-optimal launch
The rise and importance of emerging markets is challenging existing models of customer intelligence as companies strive for deep insights into unfamiliar territories. ... In competitive and fast-moving markets, the ability to respond to fresh insight is
-
China: AstraZeneca’s new engine for growth and innovation
the company’s Emerging Markets revenue,” he says. ... However IQVIA forecasts that China could exceed the size of the EU5 markets as early as 2022.
More from intelligence
Approximately 14 fully matching, plus 59 partially matching documents found.
Latest appointments
-
New faces at JPA Health Communications, GCI Health and HRW
Her more recent focus has been in conducting business in emerging markets. ... In the newly created global director role, Rees will focus on expanding the business across the company, as well as developing business opportunities in emerging markets.
-
Pfizer names Albert Bourla as COO
regional head for US vaccines, vice president for emerging markets for primary care and vice president of the US brands business within essential health.
-
Sobi appoints Torbjorn Hallberg as general counsel
Hallberg, who joins from Takeda, where he served for seven years, first as senior director and corporate counsel and then more recently as its vice president, general counsel for emerging markets.
-
Paolo Carli appointed as head of MEA at Merck
emerging markets.
-
Neovii Pharmaceuticals promotes Juergen Pohle to CEO
Prior to joining Neovii he headed up Novartis’ emerging growth markets and institutional customers businesses.
More from appointments
Approximately 0 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
Webcast: Going for growth - Maximising your return on insights in Emerging Markets
Healthcare market research in emerging markets is still evolving, so finding the insights you require and then maximising the return on those insights can be challenging. Healthcare market research in emerging ... Download this complimentary webcast in
-
New opportunities in emerging markets
However, rapid changes are underway in emerging markets. Firstly, we are seeing an expanding middle class. ... Greater purchasing power and improved market access are growing the opportunity for innovative medicines in these markets. The vast
-
Article: Spotlight on Mexico
Healthcare under AMLO – One year on. In this article, Rachel Howard and local expert Dr Xavier Tello, discuss the latest changes in the healthcare system and consider what they mean for pharmaceutical manufacturers wishing to enter the Mexican
-
Deep Dive - MINT: opportunities in ‘frontier’ markets?
What is MINT? An acronym he coined for the ‘frontier’ markets of Mexico, Indonesia, Nigeria and Turkey. ... These are the countries he believes are poised for strong economic growth, like the emerging markets of BRIC (Brazil, Russia, India and China)
-
Out of the shadows: Mental health in the Asia Pacific region
In the first of a series of articles exploring mental health in emerging markets we take an in-depth look at the situation in Asia. ... Mental health has been a peripheral issue in emerging markets for a long time, despite the severe impact it can have,
More from PMHub
Approximately 66 fully matching, plus 41 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Senior External Communications Lead
-
£Competitive Salary
-
Publications director
-
Competitive salary and bonus scheme
-
Account Director
-
£Competitive Salary
-
Account Director, Medical Education
-
Salary TBC
-
Account director
-
Competitive salary and bonus scheme
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
-
Account Manager
-
£Competitive Salary
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Experienced medical editor
-
Competitive salary and bonus scheme
-
Scientific Director
-
£60000 - £85000 per annum, Benefits: Bonus, pension, subsidised gym and much more
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
Subscribe to our email news alerts
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Merck KGaA divests allergy business to Dermapharm
- US backs Sanofi’s ‘fast-track’ coronavirus vaccine
- Genital herpes vaccine candidate heads for human studies
- Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
- Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD
- Introducing Nucleus POLAR™, a state-of-the-art external expert search engine and engagement management tool
- GSK pays $50m upfront to tap Immatics’ cell therapy platform
- Researchers discover new antibiotic using AI
- Bedrock Group celebrates a trio of new hires
- Tocagen merges with Forte Biosciences after brain cancer fail
- Immutep spikes on trial of its LAG-3 drug with Keytruda
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Novo Nordisk awakens its ‘Sleeping Beauty’
- Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
- How will the Tories’ historic win shape the NHS?
- Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
- CSR 'Christmas Spirit' 2019
- OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...
Quick links
Infographics
